338 related articles for article (PubMed ID: 27274304)
1. Marfan syndrome: current perspectives.
Pepe G; Giusti B; Sticchi E; Abbate R; Gensini GF; Nistri S
Appl Clin Genet; 2016; 9():55-65. PubMed ID: 27274304
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
[TBL] [Abstract][Full Text] [Related]
3. Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome.
Franken R; den Hartog AW; Radonic T; Micha D; Maugeri A; van Dijk FS; Meijers-Heijboer HE; Timmermans J; Scholte AJ; van den Berg MP; Groenink M; Mulder BJ; Zwinderman AH; de Waard V; Pals G
Circ Cardiovasc Genet; 2015 Apr; 8(2):383-8. PubMed ID: 25613431
[TBL] [Abstract][Full Text] [Related]
4. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial.
Radonic T; de Witte P; Baars MJ; Zwinderman AH; Mulder BJ; Groenink M;
Trials; 2010 Jan; 11():3. PubMed ID: 20067609
[TBL] [Abstract][Full Text] [Related]
5. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
Cook JR; Clayton NP; Carta L; Galatioto J; Chiu E; Smaldone S; Nelson CA; Cheng SH; Wentworth BM; Ramirez F
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):911-7. PubMed ID: 25614286
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular characteristics in Marfan syndrome and their relation to the genotype.
De Backer J
Verh K Acad Geneeskd Belg; 2009; 71(6):335-71. PubMed ID: 20232788
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?
Matt P; Habashi J; Carrel T; Cameron DE; Van Eyk JE; Dietz HC
J Thorac Cardiovasc Surg; 2008 Feb; 135(2):389-94. PubMed ID: 18242274
[TBL] [Abstract][Full Text] [Related]
8. Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.
Hofmann Bowman MA; Eagle KA; Milewicz DM
JAMA Cardiol; 2019 Jul; 4(7):702-707. PubMed ID: 31066871
[TBL] [Abstract][Full Text] [Related]
9. miR-29b participates in early aneurysm development in Marfan syndrome.
Merk DR; Chin JT; Dake BA; Maegdefessel L; Miller MO; Kimura N; Tsao PS; Iosef C; Berry GJ; Mohr FW; Spin JM; Alvira CM; Robbins RC; Fischbein MP
Circ Res; 2012 Jan; 110(2):312-24. PubMed ID: 22116819
[TBL] [Abstract][Full Text] [Related]
10. Elevated expression levels of lysyl oxidases protect against aortic aneurysm progression in Marfan syndrome.
Busnadiego O; Gorbenko Del Blanco D; González-Santamaría J; Habashi JP; Calderon JF; Sandoval P; Bedja D; Guinea-Viniegra J; Lopez-Cabrera M; Rosell-Garcia T; Snabel JM; Hanemaaijer R; Forteza A; Dietz HC; Egea G; Rodriguez-Pascual F
J Mol Cell Cardiol; 2015 Aug; 85():48-57. PubMed ID: 25988230
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin receptor blockers: a panacea for Marfan syndrome and related disorders?
Loeys BL
Drug Discov Today; 2015 Feb; 20(2):262-6. PubMed ID: 25281853
[TBL] [Abstract][Full Text] [Related]
12. Circulating transforming growth factor-beta in Marfan syndrome.
Matt P; Schoenhoff F; Habashi J; Holm T; Van Erp C; Loch D; Carlson OD; Griswold BF; Fu Q; De Backer J; Loeys B; Huso DL; McDonnell NB; Van Eyk JE; Dietz HC;
Circulation; 2009 Aug; 120(6):526-32. PubMed ID: 19635970
[TBL] [Abstract][Full Text] [Related]
13. Novel pharmacological strategies to prevent aortic complications in Marfan syndrome.
Matt P; Eckstein F
J Geriatr Cardiol; 2011 Dec; 8(4):254-7. PubMed ID: 22783312
[TBL] [Abstract][Full Text] [Related]
14. Marfan syndrome: An eyesight of syndrome.
Kumar A; Agarwal S
Meta Gene; 2014 Dec; 2():96-105. PubMed ID: 25606393
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology and Japanese clinical characteristics in Marfan syndrome.
Fujita D; Takeda N; Imai Y; Inuzuka R; Komuro I; Hirata Y
Pediatr Int; 2014 Aug; 56(4):484-91. PubMed ID: 24931486
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology and Management of Cardiovascular Manifestations in Marfan and Loeys-Dietz Syndromes.
Takeda N; Yagi H; Hara H; Fujiwara T; Fujita D; Nawata K; Inuzuka R; Taniguchi Y; Harada M; Toko H; Akazawa H; Komuro I
Int Heart J; 2016 May; 57(3):271-7. PubMed ID: 27181042
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome.
Yang HH; Kim JM; Chum E; van Breemen C; Chung AW
J Thorac Cardiovasc Surg; 2010 Aug; 140(2):305-312.e2. PubMed ID: 20189193
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial.
van Andel MM; Indrakusuma R; Jalalzadeh H; Balm R; Timmermans J; Scholte AJ; van den Berg MP; Zwinderman AH; Mulder BJM; de Waard V; Groenink M
Eur Heart J; 2020 Nov; 41(43):4181-4187. PubMed ID: 32548624
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial.
Muiño-Mosquera L; De Nobele S; Devos D; Campens L; De Paepe A; De Backer J
Acta Cardiol; 2017 Dec; 72(6):616-624. PubMed ID: 28657492
[TBL] [Abstract][Full Text] [Related]
20. The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.
Verbrugghe P; Verhoeven J; Clijsters M; Vervoort D; Schepens J; Meuris B; Herijgers P
J Cardiovasc Pharmacol; 2018 Apr; 71(4):215-222. PubMed ID: 29300219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
